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Abstract 16 
New antibiotics are urgently required to combat rising rates of resistance against all existing classes 17 
of antimicrobials. We highlight key issues that complicate the prediction of resistance evolution in 18 
the real-world and outline the ways in which these can be overcome.     19 
 20 
Introduction 21 
Globally rising rates of antimicrobial resistance (AMR) against all existing antibiotic classes 22 
combined with a near empty pharmaceutical pipeline of new antibiotic classes has given renewed 23 
urgency to drug discovery efforts1. Recent high-profile discoveries, based on novel natural product 24 
screens (e.g. teixobactin2) or modified natural products (e.g. arylomycin3), are encouraging but the 25 
evolution of resistance remains a serious concern for the long-term efficacy of new antibiotics. The 26 
standard approach for assessing the risk of resistance evolution in such studies is to measure the 27 
rate of spontaneous resistance mutation using fluctuation tests: assays where bacterial cultures are 28 
spread onto agar containing the antibiotic and the number of colony forming units compared against 29 
antibiotic-free controls4. Whole genome or targeted sequencing of resistant mutants can then identify 30 
the genetic locus (or loci) mutated and the degree of resistance provided by different mutations. 31 
While these data provide a valuable snapshot of the potential for the tested bacterium to evolve 32 
resistance via spontaneous mutation, resistance evolution in the real-world is often more complex, 33 
as is evident from older antibiotics which induce high rates of in vitro resistance but remain clinically 34 
useful (e.g. rifampicin). Our recent conversations with the pharmaceutical industry suggest that it 35 
now takes resistance evolution very seriously and implements stringent cut-offs for in vitro resistance 36 
mutation frequencies deemed acceptable for new antibiotics. An over-simplified view of resistance 37 
evolution combined with stringent in vitro targets for resistance risks halting the development of 38 
potentially useful compounds if in vitro tests over-estimate the evolutionary success of resistant 39 
genotypes (e.g. by ignoring high in vivo fitness costs). Conversely, under-estimating the in vivo 40 
evolutionary success of resistant genotypes will lead to wasted development effort.  How then can 41 
we bridge the gap between existing practice and a more realistic assessment of the risk of resistance 42 
evolution to ensure the long-term utility of new antibiotics? 43 
 44 
Mind the reality gap 45 
Here we identify four key issues that complicate the prediction of resistance evolution in the real-46 
world and outline the ways in which these can be overcome (Fig. 1).  47 
 48 
1. Population ecology of infections: All else being equal, resistance by spontaneous mutation is 49 
more likely in larger bacterial populations5. Bacterial population size varies widely between 50 
different kinds of infection, although accurate estimates of population sizes are surprisingly 51 
limited. For example, the total number of bacteria in blood stream infections caused by E. coli 52 
and S. aureus varies between approximately 103 and 108  cells (ref. 6), and pathogen densities 53 
during ventilator-associated pneumonia can exceed 106 CFU  per mL of sputum (ref. 7). 54 
However, invasion by resistant genotypes can also be affected by differential clearance of 55 
resistant versus susceptible genotypes. For example, the number of E. coli cells in urinary tract 56 
infections can reach 1010 CFU,, guaranteeing the presence of thousands of resistant mutants, 57 
but resistance evolves rarely during infection because of the high rate of turnover of bladder 58 
contents8. In contrast, chronic biofilm infections may sustain large population sizes, lower rates 59 
of population turnover and elevated mutation rates, giving rise to high levels of standing genetic 60 
variation available to natural selection9-11. Further, physiological tolerance to antibiotics can allow 61 
sufficient time for resistance mutations to arise in vivo12, which may not be observed in vitro. 62 
Improving resistance prediction requires better data on the basic population ecology parameters 63 
of different infections. 64 
2. Pre-existing resistance: Standing genetic variation (SGV) for resistance is likely to exist for 65 
new antibiotics that target cellular processes already targeted by existing drugs, or that are 66 
derived from natural antimicrobials (e.g. antimicrobial peptides13). For example, S. aureus 67 
acquired the SCCmec element years before the clinical introduction of methicillin, and methicillin 68 
use resulted in the very rapid spread of these MRSA lineages14. Selection by non-antimicrobial 69 
drugs15 and non-clinical antimicrobial agents (e.g., triclosan16,17) also risks the collateral evolution 70 
of antibiotic resistance. The vast database of genome sequences of pathogenic bacteria 71 
provides a powerful way to prospectively test for SGV at genes involved in resistance to new 72 
antibiotics by genome mining. For instance, for arylomycin, 7 resistance mutations were 73 
identified in the lepB gene3. We scanned the European Nucleotide Archive (ENA) for mutations 74 
in lepB using the search tool BIGSI18 (N=447,833 whole genome sequence datasets).  We found 75 
45,009 datasets contained a lepB gene >97% DNA identical to the lepB gene in E. coli ATCC 76 
25922, harbouring a total of 98/324 codons with at least one non-synonymous mutation. We did 77 
not find any of the 7 variants found to confer arylomycin resistance in the original study3, but we 78 
did find 82 datasets containing another amino acid substitution at one of those seven positions 79 
(L142I). This demonstrates the feasibility of estimating whether resistant variants are circulating 80 
prior to an antibiotic’s clinical use, if the genetic targets of resistance mutations are known. 81 
Alternatively, resistance determinants against new antibiotics can be detected using functional 82 
metagenomics19. Here, fragments of metagenomic DNA are expressed and screened for their 83 
effect on resistance. This approach is especially useful for detecting unknown resistance genes 84 
present in environments where natural product-derived antibiotics are naturally expressed20,21 or 85 
in animal or human microbiomes22,23. Pre-existing resistance is especially problematic if these 86 
genes become mobilised on mobile genetic elements, such as transducing phages and 87 
plasmids24. Horizontal gene transfer via mobile genetic elements, bacteriophages or via 88 
competence for transformation can strongly contribute to the rise and spread of resistance25,26. 89 
Experiments estimating rates of gene mobilisation in relevant environments27 are urgently 90 
required.  91 
3. Fitness costs and interplay with the host: Population genetic models suggest that fitness 92 
costs associated with resistance limit its persistence upon removal of the antibiotic5. Costs arise 93 
because resistance mutations may impair the normal function of the target gene or through 94 
physiological costs of expressing resistance genes or harbouring MGEs28. Fitness costs can be 95 
easily quantified using growth or competition assays in lab media and animal infection models, 96 
and these should be provided in all reports of new antibiotics28. Although there is some degree 97 
of agreement between in vivo and in vitro measures of fitness cost28,29, in vitro assays can 98 
underestimate the fitness costs of resistance that manifest in more complex infection 99 
environments30. For example, mutations conferring resistance to bacteriocin-derived avidocin 100 
antibiotics cause loss of the S-layer in Clostridium difficile. This has no effect on in vitro growth 101 
rate but makes resistant cells highly susceptible to innate immune effectors and avirulent in an 102 
in vivo infection model31. High in vitro resistance mutation rate against a new antibiotic can deter 103 
further development of a new drug, even if high fitness costs in vivo effectively limit the success 104 
of these resistant mutants in patients because of competition or immune clearance. For example, 105 
the development of mecillinam would currently be halted by pharmaceutical companies due to 106 
high resistance mutation frequencies (ranging from 8 × 10-8 to 2 × 10-5 per cell) but resistance in 107 
the clinic is rare due to the low in vivo fitness of mutants32. Accurately modelling within-host 108 
bacterial metabolism and physiology by using more realistic experimental environments, such 109 
as host-mimicking media33,34, in vitro biofilm models35,36, animal models37 or ex vivo tissue 110 
models38,39, will offer a more accurate picture of fitness costs. 111 
4. Compensatory evolution: Over time, second-site mutations that compensate for the fitness 112 
cost of the resistance mutation while leaving the resistant phenotype intact can allow persistence 113 
of resistant genotypes in vivo and in environmental reservoirs in the absence of antibiotic 114 
selection28,40. The targets of compensatory mutations can be determined using evolve-and-115 
resequence experiments where resistant mutants are serially passaged without antibiotic until 116 
they recover ancestral-level fitness41-43. For example, mutations in M. tuberculosis that 117 
compensate for the fitness cost of rifampicin resistance in vitro are found in clinical isolates and 118 
contribute to the tuberculosis epidemic44. The extent to which lab studies provide an unbiased 119 
view of compensatory evolution in the real-world is unclear45, but one promising solution to this 120 
problem is to use genome-wide association analyses of bacterial genomic datasets to link known 121 
resistance mutations with subsequent compensatory mutations. For example, acquisition of 122 
multidrug resistance plasmids in E. coli ST131 has been shown to be associated with specific 123 
regulatory mutations that may compensate the fitness cost of plasmid carriage46.  124 
 125 
Bridging the gap 126 
Ideally, evolutionary analysis of resistance should accompany in vivo experimental and clinical trials 127 
of new antibiotics. The following changes to existing practices would allow far better understanding 128 
of the potential for resistance evolution:  129 
 130 
• Appropriate choice of infection models during research & development: By considering the 131 
physicochemical environment at infection sites and its effects on bacterial growth, gene 132 
expression and physiology, will provide better estimates of likely rates of resistance emergence 133 
and associated fitness costs which may differ substantially from those observed in standard 134 
laboratory growth media34. For example, the leucyl-tRNA synthetase inhibitor GSK2251052 135 
showed limited resistance development in vitro but failed in clinical trials because of rapid 136 
emergence of resistance in treated patients47. Improved estimates of the risks of in vivo 137 
resistance would allow drug candidates to be better prioritised for progression to clinical trials, 138 
and could therefore directly benefit the pharmaceutical industry by more effectively targeting 139 
investment. 140 
• Dosing to minimise resistance selection: Massive experimental and modelling efforts are 141 
made to quantify the PK/PD of new antibiotics before clinical trial with the goal of maximizing 142 
antibiotic efficacy. Minimizing selection for resistance should also be a goal of PK/PD studies48 143 
which should employ appropriate infection models.   144 
• More intensive sampling of infections during clinical trials: Current approaches sample 145 
single colonies, ignoring the diversity present in most infections and therefore losing the 146 
opportunity to understand evolutionary processes occurring in infections49,50. More extensive 147 
culture-based sampling should be combined with deep-sequencing to quantify resistance allele 148 
frequencies and capture hard to culture organisms (e.g. persister cells, polymicrobial infections). 149 
Access for scientists to the samples from completed clinical trials would allow the development 150 
of methods and analyses for efficiently characterising the evolutionary mechanisms leading to 151 
resistance in patients. Furthermore, development of culture conditions allowing maintenance of 152 
diverse bacterial populations and/or communities in the lab would facilitate understanding how 153 
resistance evolution is a function of microbial community interactions. 154 
• Microbiome sampling in clinical trials: Antibiotic treatment often has collateral effects on the 155 
microbiome including driving lateral transfer of resistance elements at other body sites51. 156 
Combining new bioinformatics tools for resistance prediction52 with long-read or proximity ligation 157 
sequencing technologies allows localisation of resistance genes to their genomic context and 158 
the tracking of gene mobilisation and transfer53,54.   159 
 160 
These new approaches will increase the scale and cost of clinical trials in the immediate term and 161 
will require that medical funders and pharmaceutical companies embrace eco-evolutionary thinking. 162 
However, there are likely to be direct benefits in terms of more effective targeting of investment and 163 
fewer potentially useful drug candidates being discarded due to misleading in vitro resistance 164 
estimates. It is possible therefore that taking a more realistic view of resistance evolution could help 165 
to rejuvenate the antibiotic pipeline.  166 
 167 
 168 
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Figure legend 308 
Figure 1 | Predicting the evolutionary risk of resistance against new antibiotics is complicated by the 309 
complexity of real-world infections 310 
 311 
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